December 2017

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column][vc_column_text][tnc-pdf-viewer-iframe file="https://amphivena.com/wp-content/uploads/amphivena-ASH-presentation-Dec-6-2017-Final-Version.pdf" width="100%" height="800" download="true" print="true" fullscreen="true" share="true" zoom="true" open="true" pagenav="true" logo="true" find="true" current_view="true" rotate="true" handtool="true" doc_prop="true" toggle_menu="true" toggle_left="true" scroll="true" spread="true" language="en-US" page="" default_zoom="" pagemode="" iframe_title=""][/vc_column_text][/vc_column][/vc_row]...

SOUTH SAN FRANCISCO – November 29, 2017 – Amphivena Therapeutics Inc., a privately held biotechnology company developing a novel CD33/CD3 T cell engager for the treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS), announced today that it has received Orphan Drug Designation from...